AndhraNews.net
Home » Business News » 2014 » November » November 13, 2014

Rick Harrison of Television's "Pawn Stars(R)" Takes His Patient-Care Message to AHA Scientific Sessions to Raise Awareness of Very High Triglycerides as Part of National Campaign


November 13, 2014 - Bedminster, Nj And Dublin, Ireland

BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - November 13, 2014) - Making the right deal can meaningfully impact and improve your health when it comes to speaking with your doctor. Rick Harrison, star of the hit television show, "Pawn Stars®," will attend the American Heart Association's (AHA) Scientific Sessions to raise awareness of very high triglycerides (VHTG) (≥ 500 mg/dL), a condition that affects up to four million Americans.1 Mr. Harrison's AHA visit is sponsored by Amarin Corporation, plc (NASDAQ: AMRN).

Harrison is a spokesperson for Lower My Trigs™, a national awareness campaign focused on treatment for very high triglycerides. After being diagnosed with very high triglycerides, Rick was surprised to learn that there are hundreds of dietary fish oil supplements and most of those products contain DHA which can actually raise bad cholesterol.2

Known for his keen assessment of the value of rare and unique items -- from 16th century manuscripts to Elvis memorabilia -- Rick shares his journey from diagnosis to treatment, including his road to learning more about treatment myths and physician-supervised options. Rick provides his story in a video at www.lowermytrigs.com.

Together, Rick and Amarin hope to increase awareness of very high triglycerides and the importance of seeking a doctor's guidance to control this condition.

John Thero, President and Chief Executive Officer of Amarin, stated, "While Rick is unique as a person, his diagnosis and treatment story are all too common. Rick's participation at the AHA Scientific Sessions is designed to reinforce the positive role physicians can play in educating patients on the importance of testing for very high triglycerides and the importance of choosing the right treatment options under a physician's care. Rick has taken all the steps his physician recommended to get his triglyceride levels down including regular exercise, a balanced diet and taking EPA-only Vascepa® (icosapent ethyl) capsules."

About Vascepa® (icosapent ethyl) capsules
Vascepa® (icosapent ethyl) capsules, known in scientific literature as AMR101, is a highly pure-EPA omega-3 prescription product in a 1 gram capsule.

Indications and Usage

  • Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
  • The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined.

Important Safety Information for Vascepa

  • Vascepa is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of its components and should be used with caution in patients with known hypersensitivity to fish and/or shellfish.
  • The most common reported adverse reaction (incidence > 2% and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo). There was no reported adverse reaction > 3% and greater than placebo.

FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM.

About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes commitment to an ongoing outcomes study. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is an ultra-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements about the potential efficacy, safety and therapeutic benefits of Amarin's product, Amarin's clinical trial results, including statements about the clinical importance of certain parameters and the impact of Vascepa on such parameters. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, including the risk that historical clinical trial results may not be predictive of future results in replicated in larger patient populations and that studied lipid parameters may not have clinically meaningful effect or support regulatory approvals. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Availability of other information about Amarin

Investors and others should note that we communicate with our investors and the public using our company website (www.amarincorp.com), our investor relations website (http://www.amarincorp.com/investor-splash.html), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Pawn Stars® is a trademark of A&E Television Networks, LLC. The Amarin group of companies is not affiliated or associated with A&E Television Networks, LLC.

1 Christian JB, Bourgeois N, Snipes R, Lowe KA. Prevalence of Severe (500 to 2,000 mg/dl) Hypertriglyceridemia in United States Adults. Am J Cardiol. 2011;107:891-897.

2 Collins N, Tighe AP, Brunton SA, Kris-Etherton PM. Differences between Dietary Supplement and Prescription Drug Omega-3 Fatty Acid Formulations: A Legislative and Regulatory Perspective. J Am Coll Nutr. 2008;27(6):659-666.

Amarin contact information

Michael Farrell
Investor Relations and Corporate Communications
Amarin Corporation plc
(908) 719-1315
investor.relations@amarincorp.com

Graham Morrell
Trout Group 
(646) 378-2954
gmorrell@troutgroup.com

MarketWire

Comment on this story

Share